


1 **Supplementary information**

2 **Supplementary Figure S1.** Participant flow diagram. The cohorts were primed with the primary
3 series of CV and received a reduced dose (experimental group) or standard dose (comparative
4 group) of the mRNA vaccine.


Two doses of CoronaVac-immunized healthy adults



[‡] Previously enrolled by Assawakosri *et al.*, 2022

5
6
7
8


9 **Supplementary Figure S2.** Reactogenicity after receiving mRNA vaccine for 7 days post-
 10 vaccination. The participants received two completed doses of the inactivated vaccine,
 11 CoronaVac, followed by A) 15 µg-BNT162b2, B) 30 µg-BNT162b2, C) 50 µg-mRNA-1273, or
 12 D) 100 µg-mRNA-1273. Participant percentages are shown on the Y-axis. Swelling and redness
 13 were graded by measuring the diameter area as mild (<5 cm), moderate (5 to <10 cm), and
 14 severe (≥10 cm). Fever was defined as mild (38.0-38.5 °C), moderate (38.5-39.0 °C), and severe
 15 (39.0 °C). Local and systemic symptoms were graded as mild (easily tolerated with no limitation
 16 on regular activity), moderate (some limitation of daily activity), and severe (unable to perform
 17 the regular daily activity).



18
 19
 20
 21
 22
 23
 24
 25

26 **Supplementary Figure S3.** IgG anti nucleoprotein (N) of SARS-CoV-2 index (S/C). Serum
27 samples were obtained from participants who received two completed doses of the inactivated
28 vaccine, CoronaVac, followed by 15 µg (reduced) mRNA vaccine–BNT162b2, 30 µg (standard)
29 mRNA vaccine–BNT162b2, 50 µg (reduced) mRNA-1273, or 100 µg (standard) mRNA-1273.
30 Lines represent the median (interquartile range).

31



32

33

34

35

36

37

38

39 **Supplementary Table S1.** Patient serum responses during study trials.

	BNT162b2 (15 µg)	BNT162b2 (30 µg)^y	mRNA-1273 (50 µg)	mRNA-1273 (100 µg)^y
Humoral responses				
Ig anti-RBD (U/mL)				
V1 (Baseline), n	59	54	51	58
GMT (95% CI)	45.01 (32.86-61.65)	41.67 (31.38-55.32)	41.06 (29.05-58.03)	27.07 (20.44-35.84)
V2 (Second visit), n	56	54	51	57
GMT (95% CI)	28413 (24781-32578)	31793 (27428-36852)	41171 (34563-49043)	51979 (43920- 61516)
V3 (Third visit), n	56	54	49	56
GMT (95% CI)	21299 (18390-24667)	21053 (18145-24428)	27282 (23082-32245)	33519 (28228- 39802)
IgG anti-RBD (BAU/mL)				
V1 (Baseline), n	59	54	51	58
GMT (95% CI)	22.91 (17.88-29.37)	26.01 (21.16-31.97)	22.52 (17.70-28.64)	18.13 (14.78-22.23)
V2 (Second visit), n	56	54	51	57
GMT (95% CI)	4609 (4009-5299)	4878 (4222-5636)	7476 (6167-9062)	8901 (7471-10605)
V3 (Third visit), n	56	54	49	56
GMT (95% CI)	3994 (3455-4618)	3837 (3292-4472)	5416 (4523-6485)	6570 (5694-7580)
IgG anti-N (S/C)				
V1 (Baseline), n	59	54	51	58
Median (IQR)	0.09 (0.07-0.19)	0.15 (0.10-0.36)	0.15 (0.09-0.23)	0.13 (0.07-0.33)
V2 (Second visit), n	56	54	51	57
Median (IQR)	0.15 (0.08-0.29)	0.14 (0.09-0.41)	0.17 (0.09-0.25)	0.14 (0.09-0.37)
V3 (Third visit), n	56	54	49	56
Median (IQR)	0.15 (0.07-0.27)	0.12 (0.08-0.31)	0.15 (0.07-0.22)	0.12 (0.07-0.31)
Neutralization assays: VNT-Delta (%inhibition)				
V3 (Third visit), n	29	30	30	30
Median (IQR)	97.4 (97.2-97.5)	97.5 (97.3-97.6)	97.4 (97.2-97.4)	98.2 (98.2-98.3)
Neutralization assays: VNT-Omicron (%inhibition)				
V3 (Third visit), n	29	30	30	30
Median (IQR)	71.2 (43.7-84.2)	53.5 (26.3-70.0)	61.1 (44.5-81.5)	76.7 (60.6-91.6)
Neutralization assay: FRNT-Delta (dilution)				
V3 (Third visit), n	30	30	30	30
GMT (95% CI)	1505 (1126- 2012)	1285 (982.2-1680)	2088 (1441-3025)	2168 (1627-2889)
Neutralization assay: FRNT-Omicron (dilution)				
V3 (Third visit), n	30	30	30	30
GMT (95% CI)	343.4 (244.6- 482.1)	276.6 (190.1-402.3)	521.1 (352.4-770.7)	512.5 (358.7-732.2)

T-cell responses**IFN- γ CD4⁺ (IU/mL)**

V1 (Baseline), n	30	27	29	31
Median (IQR)	0.01 (-0.02-0.103)	0.05 (0.01-0.19)	0.03 (0.01-0.08)	0.03 (-0.01-0.20)
V2 (Second visit), n	30	27	28	31
Median (IQR)	0.72 (0.18 - 1.72)	1.12 (0.41-2.22)	1.18 (0.19-2.39)	0.90 (0.25-1.78)
V3 (Third visit), n	30	27	29	31
Median (IQR)	0.30 (0.15-1.22)	0.74 (0.20-1.46)	0.66 (0.15-1.46)	0.77 (0.26-1.83)

IFN- γ CD4⁺ CD8⁺ (IU/mL)

V1 (Baseline), n	30	27	29	31
Median (IQR)	0.02 (-0.02-0.20)	0.10 (0.02-0.23)	0.03 (-0.01-0.13)	0.11 (0.00-0.31)
V2 (Second visit), n	30	27	28	31
Median (IQR)	1.00 (0.34-3.19)	2.22 (0.82-2.70)	1.59 (0.24-3.11)	1.68 (0.39-2.68)
V3 (Third visit), n	30	27	29	31
Median (IQR)	0.44 (0.14-2.11)	1.02 (0.29-2.40)	0.93 (0.35-1.88)	1.03 (0.40-2.31)

40 μg indicates an amount of SARS-CoV-2 Spike protein encoded mRNA

41 ^y the comparative group represents a regular dose of each mRNA COVID-19 vaccine as

42 previously reported by Assawakosri et al., 2011.

43